SG10202103341SA - Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms - Google Patents

Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms

Info

Publication number: SG10202103341SA
Authority: SG; Singapore
Prior art keywords: myeloproliferative; treatment; telomerase inhibitors; neoplasms; disorders
Prior art date: 2012-12-07

Application number

SG10202103341SA

Inventor

Monic Stuart

Stephen Kelsey

Original Assignee

Geron Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-07

Filing date

2013-11-15

Publication date

2021-05-28

2013-03-15 Priority claimed from US13/841,711 external-priority patent/US9375485B2/en

2013-11-15 Application filed by Geron Corp filed Critical Geron Corp

2021-05-28 Publication of SG10202103341SA publication Critical patent/SG10202103341SA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Diabetes (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Virology (AREA)
Microbiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Physiology (AREA)
Otolaryngology (AREA)
Nutrition Science (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SG10202103341SA 2012-12-07 2013-11-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms SG10202103341SA (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201261734941P	2012-12-07	2012-12-07
US201361799069P	2013-03-15	2013-03-15
US13/841,711 US9375485B2 (en)	2012-12-07	2013-03-15	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US201361900347P	2013-11-05	2013-11-05

Publications (1)

Publication Number	Publication Date
SG10202103341SA true SG10202103341SA (en)	2021-05-28

Family

ID=50883867

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SG10202103341SA SG10202103341SA (en)	2012-12-07	2013-11-15	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
SG10201802926XA SG10201802926XA (en)	2012-12-07	2013-11-15	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
SG11201504383TA SG11201504383TA (en)	2012-12-07	2013-11-15	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
SG10201802926XA SG10201802926XA (en)	2012-12-07	2013-11-15	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
SG11201504383TA SG11201504383TA (en)	2012-12-07	2013-11-15	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms

Country Status (37)

Country	Link
EP (3)	EP3456333B8 (en)
JP (6)	JP6433911B2 (en)
KR (4)	KR102662590B1 (en)
CN (2)	CN111617252A (en)
AP (1)	AP2015008504A0 (en)
AU (4)	AU2013356533B2 (en)
BR (1)	BR112015013260A2 (en)
CA (2)	CA2892907C (en)
CL (2)	CL2015001530A1 (en)
CY (2)	CY1122169T1 (en)
DK (3)	DK2928477T3 (en)
EA (1)	EA032973B1 (en)
ES (3)	ES2789176T3 (en)
FI (2)	FI3646876T3 (en)
FR (1)	FR25C1016I1 (en)
HK (1)	HK1210940A1 (en)
HR (3)	HRP20240624T1 (en)
HU (4)	HUE066402T2 (en)
IL (3)	IL280144B2 (en)
LT (4)	LT3456333T (en)
MA (2)	MA38193B1 (en)
ME (1)	ME03538B (en)
MX (3)	MX372753B (en)
MY (2)	MY200076A (en)
NL (1)	NL301326I2 (en)
NZ (1)	NZ708920A (en)
PH (2)	PH12019501008A1 (en)
PL (3)	PL2928477T3 (en)
PT (3)	PT3456333T (en)
RS (2)	RS59363B1 (en)
SG (3)	SG10202103341SA (en)
SI (3)	SI3646876T1 (en)
SM (2)	SMT202000328T1 (en)
TN (1)	TN2015000249A1 (en)
UA (3)	UA128370C2 (en)
WO (1)	WO2014088785A1 (en)
ZA (3)	ZA201504124B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3296312B1 (en)	2004-07-02	2021-03-17	Geron Corporation	Synthesis of protected 3'-amino 5'-phosphoramidite nucleoside monomers
US9375485B2 (en)	2012-12-07	2016-06-28	Geron Corporation	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
KR20160045081A (en)	2013-08-07	2016-04-26	인사이트 코포레이션	Sustained release dosage forms for a jak1 inhibitor
AU2014346840B2 (en) *	2013-11-06	2020-02-06	Mayo Foundation For Medical Education And Research	Methods and materials for treating hematological malignancies
EA035885B1 (en)	2015-04-23	2020-08-27	Джерон Корпорейшн	Methods of polynucleotide preparation using multivalent cation salt compositions
EP3318276A1 (en) *	2016-11-04	2018-05-09	Janssen Biotech, Inc.	Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
KR20250151565A (en) *	2017-07-28	2025-10-21	제론 코포레이션	Methods of treating myelodysplastic syndrome
IL308399B2 (en)	2018-04-30	2025-08-01	Kartos Therapeutics Inc	Cancer treatment methods
US12268681B2 (en)	2018-05-25	2025-04-08	Kartos Therapeutics, Inc.	Methods of treating myeloproliferative neoplasms
CN112770783B (en) *	2018-07-31	2025-02-25	美国杰龙生物医药公司	Methods for identifying patients who may benefit from telomerase inhibitor therapy
AU2019389005B2 (en)	2018-11-29	2024-06-20	Geron Corporation	Methods of treating myelodysplastic syndrome
JP7767279B2 (en) *	2019-11-04	2025-11-11	ジェロン・コーポレーション	Use of Janus Kinase Inhibitors and Telomerase Inhibitors for the Treatment of Myeloproliferative Neoplasms - Patent application
JP2021157248A (en) *	2020-03-25	2021-10-07	パイオニア株式会社	State output device
KR20230041707A (en) *	2020-07-17	2023-03-24	제론 코포레이션	Subcutaneous Telomerase Inhibitor Compositions and Methods of Use Thereof
EP4281560A4 (en) *	2021-01-22	2025-04-16	The Regents of the University of California	Methods for treating and ameliorating cancer
WO2024259369A1 (en) *	2023-06-14	2024-12-19	Rarecells Inc.	Compositions targeting giant cells in blood disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5489508A (en)	1992-05-13	1996-02-06	University Of Texas System Board Of Regents	Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5958680A (en)	1994-07-07	1999-09-28	Geron Corporation	Mammalian telomerase
US5583016A (en)	1994-07-07	1996-12-10	Geron Corporation	Mammalian telomerase
US5760062A (en)	1995-04-18	1998-06-02	Geron Corporation	Telomerase inhibitors
US5656638A (en)	1995-04-18	1997-08-12	Geron Corporation	Telomerase inhibitors
US5863936A (en)	1995-04-18	1999-01-26	Geron Corporation	Telomerase inhibitors
US5770613A (en)	1995-09-29	1998-06-23	Geron Corporation	Telomerase inhibitors
US5767278A (en)	1995-10-06	1998-06-16	Geron Corporation	Telomerase inhibitors
US6261836B1 (en)	1996-10-01	2001-07-17	Geron Corporation	Telomerase
US6444650B1 (en)	1996-10-01	2002-09-03	Geron Corporation	Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
CA2274586A1 (en)	1996-12-20	1998-07-02	Geron Corporation	Methods for detecting and inhibiting the rna component of telomerase
US6331399B1 (en)	2000-05-16	2001-12-18	Isis Pharmaceuticals, Inc.	Antisense inhibition of tert expression
AU2004209428A1 (en) *	2003-01-31	2004-08-19	Jessie L.-S. Au	Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors
CN1244592C (en) *	2003-07-11	2006-03-08	暨南大学	Antisense nucleic acid having inhibiting leukemid cell telomerase activity and its application
AU2004271215B2 (en)	2003-09-09	2009-07-16	Geron Corporation	Modified oligonucleotides for telomerase inhibition
US20050282893A1 (en)	2004-01-30	2005-12-22	Au Jessie L	Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
EP3296312B1 (en)	2004-07-02	2021-03-17	Geron Corporation	Synthesis of protected 3'-amino 5'-phosphoramidite nucleoside monomers
FR2877013A1 (en)	2004-10-27	2006-04-28	Assist Publ Hopitaux De Paris	INDENTIFICATION OF A JAK2 MUTATION INVOLVED IN THE VAQUEZ POLYGLOBULIA
US20060166221A1 (en)	2005-01-21	2006-07-27	Bahou Wadie F	Methods of diagnosing essential thrombocythemia
EP1876893B1 (en)	2005-04-15	2012-04-11	Geron Corporation	Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2006113426A2 (en) *	2005-04-15	2006-10-26	Geron Corporation	Cancer treatment by combined inhibition of telomerase and tubulin activities
US20070224598A1 (en)	2006-03-15	2007-09-27	The Methodist Hospital Research Institute	System and method for detection of mutations in JAK2 polynucleotides
US20080021013A1 (en)	2006-07-21	2008-01-24	Cephalon, Inc.	JAK inhibitors for treatment of myeloproliferative disorders
EP4600359A2 (en)	2006-10-30	2025-08-13	Geron Corporation	Combined telomerase inhibitor and gemcitabine for the treatment of cancer
CN101220044B (en) *	2008-01-21	2010-06-02	中国药科大学	Telomerase inhibitor and its preparation method and use

2013
- 2013-11-15 UA UAA202100419A patent/UA128370C2/en unknown
- 2013-11-15 BR BR112015013260-0A patent/BR112015013260A2/en not_active Application Discontinuation
- 2013-11-15 DK DK13861008.4T patent/DK2928477T3/en active
- 2013-11-15 HU HUE19187756A patent/HUE066402T2/en unknown
- 2013-11-15 KR KR1020217026717A patent/KR102662590B1/en active Active
- 2013-11-15 ES ES18196690T patent/ES2789176T3/en active Active
- 2013-11-15 HK HK15111700.1A patent/HK1210940A1/en unknown
- 2013-11-15 SG SG10202103341SA patent/SG10202103341SA/en unknown
- 2013-11-15 CA CA2892907A patent/CA2892907C/en active Active
- 2013-11-15 ES ES19187756T patent/ES2982897T3/en active Active
- 2013-11-15 ME MEP-2019-273A patent/ME03538B/en unknown
- 2013-11-15 PH PH1/2019/501008A patent/PH12019501008A1/en unknown
- 2013-11-15 SG SG10201802926XA patent/SG10201802926XA/en unknown
- 2013-11-15 MA MA38193A patent/MA38193B1/en unknown
- 2013-11-15 HU HUE13861008A patent/HUE045098T2/en unknown
- 2013-11-15 KR KR1020157017240A patent/KR102294819B1/en active Active
- 2013-11-15 LT LTEP18196690.4T patent/LT3456333T/en unknown
- 2013-11-15 EP EP18196690.4A patent/EP3456333B8/en active Active
- 2013-11-15 UA UAA201505480A patent/UA117116C2/en unknown
- 2013-11-15 EA EA201590878A patent/EA032973B1/en unknown
- 2013-11-15 RS RSP20191271 patent/RS59363B1/en unknown
- 2013-11-15 SG SG11201504383TA patent/SG11201504383TA/en unknown
- 2013-11-15 PT PT181966904T patent/PT3456333T/en unknown
- 2013-11-15 EP EP19187756.2A patent/EP3646876B1/en active Active
- 2013-11-15 HR HRP20240624TT patent/HRP20240624T1/en unknown
- 2013-11-15 CA CA3188494A patent/CA3188494A1/en active Pending
- 2013-11-15 RS RS20200723A patent/RS60401B1/en unknown
- 2013-11-15 HR HRP20191784TT patent/HRP20191784T1/en unknown
- 2013-11-15 WO PCT/US2013/070437 patent/WO2014088785A1/en not_active Ceased
- 2013-11-15 LT LTEP19187756.2T patent/LT3646876T/en unknown
- 2013-11-15 DK DK18196690.4T patent/DK3456333T3/en active
- 2013-11-15 IL IL280144A patent/IL280144B2/en unknown
- 2013-11-15 MY MYPI2020000946A patent/MY200076A/en unknown
- 2013-11-15 FI FIEP19187756.2T patent/FI3646876T3/en active
- 2013-11-15 KR KR1020237005641A patent/KR20230028590A/en not_active Ceased
- 2013-11-15 MA MA45504A patent/MA45504B1/en unknown
- 2013-11-15 PT PT138610084T patent/PT2928477T/en unknown
- 2013-11-15 ES ES13861008T patent/ES2744790T3/en active Active
- 2013-11-15 IL IL317233A patent/IL317233A/en unknown
- 2013-11-15 SM SM20200328T patent/SMT202000328T1/en unknown
- 2013-11-15 DK DK19187756.2T patent/DK3646876T3/en active
- 2013-11-15 PT PT191877562T patent/PT3646876T/en unknown
- 2013-11-15 CN CN202010575187.3A patent/CN111617252A/en active Pending
- 2013-11-15 SI SI201332080T patent/SI3646876T1/en unknown
- 2013-11-15 AU AU2013356533A patent/AU2013356533B2/en active Active
- 2013-11-15 HU HUE18196690A patent/HUE049858T2/en unknown
- 2013-11-15 NZ NZ708920A patent/NZ708920A/en unknown
- 2013-11-15 UA UAA201800703A patent/UA126015C2/en unknown
- 2013-11-15 LT LTEP13861008.4T patent/LT2928477T/en unknown
- 2013-11-15 JP JP2015546492A patent/JP6433911B2/en active Active
- 2013-11-15 CN CN201380069553.6A patent/CN104936602B/en active Active
- 2013-11-15 AP AP2015008504A patent/AP2015008504A0/en unknown
- 2013-11-15 MX MX2015007169A patent/MX372753B/en active IP Right Grant
- 2013-11-15 SI SI201331556T patent/SI2928477T1/en unknown
- 2013-11-15 PL PL13861008T patent/PL2928477T3/en unknown
- 2013-11-15 EP EP13861008.4A patent/EP2928477B1/en active Active
- 2013-11-15 SI SI201331716T patent/SI3456333T1/en unknown
- 2013-11-15 PL PL18196690T patent/PL3456333T3/en unknown
- 2013-11-15 MY MYPI2015001459A patent/MY180634A/en unknown
- 2013-11-15 SM SM20190567T patent/SMT201900567T1/en unknown
- 2013-11-15 KR KR1020257024576A patent/KR20250114449A/en active Pending
- 2013-11-15 PL PL19187756.2T patent/PL3646876T3/en unknown
2015
- 2015-06-04 CL CL2015001530A patent/CL2015001530A1/en unknown
- 2015-06-05 MX MX2020003276A patent/MX2020003276A/en unknown
- 2015-06-05 PH PH12015501282A patent/PH12015501282B1/en unknown
- 2015-06-05 TN TNP2015000249A patent/TN2015000249A1/en unknown
- 2015-06-05 MX MX2022015437A patent/MX2022015437A/en unknown
- 2015-06-07 IL IL23926615A patent/IL239266B/en active IP Right Grant
- 2015-06-08 ZA ZA2015/04124A patent/ZA201504124B/en unknown
2017
- 2017-08-24 CL CL2017002156A patent/CL2017002156A1/en unknown
- 2017-12-04 JP JP2017232485A patent/JP6998191B2/en active Active
2018
- 2018-12-20 AU AU2018282364A patent/AU2018282364A1/en not_active Abandoned
2019
- 2019-10-14 CY CY20191101076T patent/CY1122169T1/en unknown
- 2019-12-23 JP JP2019231517A patent/JP2020041001A/en active Pending
2020
- 2020-06-23 CY CY20201100568T patent/CY1123206T1/en unknown
- 2020-06-24 HR HRP20200993TT patent/HRP20200993T1/en unknown
- 2020-11-09 AU AU2020267142A patent/AU2020267142C1/en active Active
2021
- 2021-11-12 ZA ZA2021/08991A patent/ZA202108991B/en unknown
2022
- 2022-01-06 JP JP2022000951A patent/JP7288098B2/en active Active
- 2022-10-12 JP JP2022163881A patent/JP2022179684A/en not_active Withdrawn
- 2022-11-11 ZA ZA2022/12327A patent/ZA202212327B/en unknown
2024
- 2024-05-13 AU AU2024203138A patent/AU2024203138A1/en active Pending
2025
- 2025-05-05 NL NL301326C patent/NL301326I2/en unknown
- 2025-05-06 LT LTPA2025517C patent/LTPA2025517I1/lt unknown
- 2025-05-07 FI FIC20250019C patent/FIC20250019I1/en unknown
- 2025-05-07 FR FR25C1016C patent/FR25C1016I1/en active Active
- 2025-05-07 HU HUS2500019C patent/HUS2500019I1/en unknown
- 2025-05-12 JP JP2025080100A patent/JP2025109842A/en active Pending

Also Published As

Publication number	Publication date
MY180634A (en)	2020-12-03
CY1123206T1 (en)	2021-10-29
MA45504A1 (en)	2020-05-29
EP3456333B1 (en)	2020-04-01
SG10201802926XA (en)	2018-05-30
MA45504B1 (en)	2021-10-29
JP2018035196A (en)	2018-03-08
RS60401B1 (en)	2020-07-31
EA201590878A1 (en)	2016-04-29
FR25C1016I1 (en)	2025-06-20
DK3646876T3 (en)	2024-05-06
FIC20250019I1 (en)	2025-05-07
CL2015001530A1 (en)	2016-03-28
MX2022015437A (en)	2023-01-11
PL3646876T3 (en)	2024-07-22
LT2928477T (en)	2019-10-10
JP6998191B2 (en)	2022-02-04
PL3456333T3 (en)	2020-09-21
WO2014088785A8 (en)	2015-07-16
CN104936602B (en)	2020-07-17
EA032973B1 (en)	2019-08-30
DK2928477T3 (en)	2019-10-07
EP3646876A1 (en)	2020-05-06
KR20150091130A (en)	2015-08-07
JP7288098B2 (en)	2023-06-06
SMT201900567T1 (en)	2019-11-13
NZ748134A (en)	2020-10-30
HUE066402T2 (en)	2024-07-28
MX2020003276A (en)	2020-07-20
CA3188494A1 (en)	2014-06-12
IL239266A0 (en)	2015-07-30
IL280144B1 (en)	2025-01-01
ZA202212327B (en)	2025-03-26
MY200076A (en)	2023-12-06
HRP20191784T1 (en)	2019-12-27
SG11201504383TA (en)	2015-07-30
JP2020041001A (en)	2020-03-19
HUS2500019I1 (en)	2025-05-28
AU2013356533B2 (en)	2018-09-27
IL317233A (en)	2025-01-01
HRP20240624T1 (en)	2024-08-02
DK3456333T3 (en)	2020-05-18
IL280144A (en)	2021-03-01
RS59363B1 (en)	2019-11-29
ES2982897T3 (en)	2024-10-18
MA38193A1 (en)	2017-12-29
UA117116C2 (en)	2018-06-25
WO2014088785A1 (en)	2014-06-12
PH12015501282A1 (en)	2015-08-24
SI3646876T1 (en)	2024-07-31
HK1210940A1 (en)	2016-05-13
EP3646876B1 (en)	2024-02-14
UA128370C2 (en)	2024-06-26
CN104936602A (en)	2015-09-23
JP2025109842A (en)	2025-07-25
LT3646876T (en)	2024-05-10
AU2018282364A1 (en)	2019-05-23
BR112015013260A2 (en)	2018-02-06
PT2928477T (en)	2019-10-25
SI3456333T1 (en)	2020-10-30
PT3646876T (en)	2024-05-15
ZA201504124B (en)	2017-05-31
ZA202108991B (en)	2023-05-31
HRP20200993T1 (en)	2020-11-27
HUE045098T2 (en)	2019-12-30
KR20210107906A (en)	2021-09-01
MX2015007169A (en)	2016-03-31
AP2015008504A0 (en)	2015-06-30
CL2017002156A1 (en)	2018-05-04
EP3456333B8 (en)	2020-05-13
JP2022179684A (en)	2022-12-02
IL280144B2 (en)	2025-05-01
AU2013356533A1 (en)	2014-06-12
CA2892907C (en)	2023-03-21
JP6433911B2 (en)	2018-12-05
NZ708920A (en)	2020-08-28
CY1122169T1 (en)	2020-11-25
PH12015501282B1 (en)	2015-08-24
CN111617252A (en)	2020-09-04
KR20230028590A (en)	2023-02-28
KR20250114449A (en)	2025-07-29
AU2020267142A1 (en)	2020-12-03
FI3646876T3 (en)	2024-05-14
AU2020267142C1 (en)	2024-08-08
NL301326I2 (en)	2025-07-31
ES2744790T3 (en)	2020-02-26
PH12019501008A1 (en)	2022-11-14
EP2928477A4 (en)	2016-09-21
ES2789176T3 (en)	2020-10-26
SMT202000328T1 (en)	2020-07-08
IL239266B (en)	2019-11-28
LT3456333T (en)	2020-06-25
UA126015C2 (en)	2022-08-03
SI2928477T1 (en)	2019-11-29
TN2015000249A1 (en)	2016-10-03
KR102294819B1 (en)	2021-09-01
AU2020267142B2 (en)	2024-05-16
KR102662590B1 (en)	2024-05-03
MA38193B1 (en)	2018-12-31
CA2892907A1 (en)	2014-06-12
HK1212226A1 (en)	2016-06-10
EP2928477A1 (en)	2015-10-14
HUE049858T2 (en)	2020-11-30
EP2928477B1 (en)	2019-07-24
EP3456333A1 (en)	2019-03-20
PT3456333T (en)	2020-06-01
PL2928477T3 (en)	2020-03-31
LTPA2025517I1 (en)	2025-05-26
JP2022050537A (en)	2022-03-30
JP2016504307A (en)	2016-02-12
AU2024203138A1 (en)	2024-07-25
ME03538B (en)	2020-07-20
MX372753B (en)	2020-06-26

Publication	Publication Date	Title
ZA202108991B (en)	2023-05-31	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
IL283943B1 (en)	2023-04-01	Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
IL266582A (en)	2019-07-31	Compositions and methods for the treatment of hemoglobinopathies
IL239355A0 (en)	2015-07-30	Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
ZA201607980B (en)	2022-04-28	Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP2890440A4 (en)	2016-06-08	Devices and methods for the treatment of vascular disease
ZA201408055B (en)	2016-03-30	Compositions and methods for the treatment of local pain
IL234841A0 (en)	2014-12-31	Dosage forms of halofuginone and methods of use
IL235127A (en)	2017-12-31	Hpn-100 for use in the treatment of nitrogen retention disorders
ZA201501503B (en)	2016-01-27	Bio-inoculant and use thereof for treatment of effluents
ZA201408060B (en)	2016-03-30	Compositions and methods for the treatment of neurological disorders
SI2846805T1 (en)	2019-04-30	Treatment of addiction and impulse-control disorders using pde7 inhibitors
ZA201408061B (en)	2016-04-28	Compositions and methods for the treatment of neurological disorders
LT2846805T (en)	2019-02-25	Treatment of addiction and impulse-control disorders using pde7 inhibitors